These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 30115524)

  • 21. Safety of HPV vaccines in the age of nonavalent vaccination.
    Quattrone F; Canale A; Filippetti E; Tulipani A; Porretta A; Lopalco PL
    Minerva Pediatr; 2018 Feb; 70(1):59-66. PubMed ID: 29363293
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human papillomavirus vaccine coverage in Rwanda: A population-level analysis by birth cohort.
    Sayinzoga F; Umulisa MC; Sibomana H; Tenet V; Baussano I; Clifford GM
    Vaccine; 2020 May; 38(24):4001-4005. PubMed ID: 32336599
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Safety of the bivalent human papillomavirus vaccine--results following administration of more than 192,000 doses].
    van der Maas NA; Kemmeren JM; de Melker HE
    Ned Tijdschr Geneeskd; 2009; 153():A964. PubMed ID: 19930738
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study.
    Heijstek MW; Scherpenisse M; Groot N; Tacke C; Schepp RM; Buisman AM; Berbers GA; van der Klis FR; Wulffraat NM
    Ann Rheum Dis; 2014 Aug; 73(8):1500-7. PubMed ID: 23723319
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence of new-onset autoimmune disease in girls and women with pre-existing autoimmune disease after quadrivalent human papillomavirus vaccination: a cohort study.
    Grönlund O; Herweijer E; Sundström K; Arnheim-Dahlström L
    J Intern Med; 2016 Dec; 280(6):618-626. PubMed ID: 27478093
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Infections in temporal proximity to HPV vaccination and adverse effects following vaccination in Denmark: A nationwide register-based cohort study and case-crossover analysis.
    Krogsgaard LW; Petersen I; Plana-Ripoll O; Bech BH; Lützen TH; Thomsen RW; Rytter D
    PLoS Med; 2021 Sep; 18(9):e1003768. PubMed ID: 34495975
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human papillomavirus vaccination coverage in Luxembourg - Implications of lowering and restricting target age groups.
    Latsuzbaia A; Arbyn M; Weyers S; Mossong J
    Vaccine; 2018 Apr; 36(18):2411-2416. PubMed ID: 29602702
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Coverage of the English national human papillomavirus (HPV) immunisation programme among 12 to 17 year-old females by area-level deprivation score, England, 2008 to 2011.
    Hughes A; Mesher D; White J; Soldan K
    Euro Surveill; 2014 Jan; 19(2):. PubMed ID: 24457007
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls.
    Medina DM; Valencia A; de Velasquez A; Huang LM; Prymula R; García-Sicilia J; Rombo L; David MP; Descamps D; Hardt K; Dubin G;
    J Adolesc Health; 2010 May; 46(5):414-21. PubMed ID: 20413076
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes.
    Barzon L; Squarzon L; Masiero S; Pacenti M; Marcati G; Mantelli B; Gabrielli L; Pascucci MG; Lazzarotto T; Caputo A; Palù G
    Vaccine; 2014 Sep; 32(41):5357-62. PubMed ID: 25045814
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Socioeconomic predictors of referral to a diagnostic centre on suspected adverse events following HPV vaccination.
    Weye N; Fonager K; Lützen T; Rytter D
    Eur J Public Health; 2018 Dec; 28(6):1109-1113. PubMed ID: 29800097
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inconclusive evidence for non-inferior immunogenicity of two- compared with three-dose HPV immunization schedules in preadolescent girls: A systematic review and meta-analysis.
    Donken R; Knol MJ; Bogaards JA; van der Klis FR; Meijer CJ; de Melker HE
    J Infect; 2015 Jul; 71(1):61-73. PubMed ID: 25709084
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.
    Apter D; Wheeler CM; Paavonen J; Castellsagué X; Garland SM; Skinner SR; Naud P; Salmerón J; Chow SN; Kitchener HC; Teixeira JC; Jaisamrarn U; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Mindel A; de Sutter P; Hardt K; Zahaf T; Descamps D; Struyf F; Lehtinen M; Dubin G;
    Clin Vaccine Immunol; 2015 Apr; 22(4):361-73. PubMed ID: 25651922
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association Between Human Papillomavirus Vaccination and Primary Ovarian Insufficiency in a Nationwide Cohort.
    Hviid A; Myrup Thiesson E
    JAMA Netw Open; 2021 Aug; 4(8):e2120391. PubMed ID: 34436612
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of determinants associated with uptake of the first dose of the human papillomavirus vaccine in Denmark.
    Amdisen L; Kristensen ML; Rytter D; Mølbak K; Valentiner-Branth P
    Vaccine; 2018 Sep; 36(38):5747-5753. PubMed ID: 30111513
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccination of boys or catch-up of girls above 11 years of age with the HPV-16/18 AS04-adjuvanted vaccine: where is the greatest benefit for cervical cancer prevention in Italy?
    Bonanni P; Gabutti G; Demarteau N; Boccalini S; La Torre G
    BMC Infect Dis; 2015 Sep; 15():377. PubMed ID: 26381489
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2013 - United States.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2013 Jul; 62(29):591-5. PubMed ID: 23884346
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in adolescents aged 12-15 years: Interim analysis of a large community-randomized controlled trial.
    Lehtinen M; Eriksson T; Apter D; Hokkanen M; Natunen K; Paavonen J; Pukkala E; Angelo MG; Zima J; David MP; Datta S; Bi D; Struyf F; Dubin G
    Hum Vaccin Immunother; 2016 Dec; 12(12):3177-3185. PubMed ID: 27841725
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human papillomavirus vaccine introduction--the first five years.
    Markowitz LE; Tsu V; Deeks SL; Cubie H; Wang SA; Vicari AS; Brotherton JM
    Vaccine; 2012 Nov; 30 Suppl 5():F139-48. PubMed ID: 23199957
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Age impact on human papillomavirus vaccination in France in 2014: A study from the National Health Insurance Database.
    Héquet D; Pouget N; Estevez JP; Robain M; Rouzier R
    Bull Cancer; 2015 Nov; 102(11):892-7. PubMed ID: 26526386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.